The company is currently engaged in drug development programs based on repurposing a US Food and Drug Administration-approved cannabinoid, Dronabinol, which is also known as marijuana.

In 2019, Therapix had been in discussions with other companies about a merger, but as of November 2019, none of these had come to fruition.